tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000842023 /10-K filed Aug 24, 2026, compared with Aug 22, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
TECHMRNAVEEVPODDWSTRVTY
Nasdaq Health care · Biotechnology

Bio-Techne TECH

TECH quote by TradingView
Headquarters
Minneapolis, MN
CEO
Kim Kelderman
Next results
around Feb 3, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2026

Revenue of $1.2B through the costs to a net profit of $181.8M · income statement of the 10-K

21% operating margin
Revenue to Gross profit: $799.1MRevenue to Cost of revenue: $416.0MGross profit to Operating profit: $251.9MGross profit to Operating expenses: $547.2MOperating profit to Net profit: $181.8MOperating profit to Tax & other: $70.0MOperating expenses to R&D: $94.8MOperating expenses to SG&A: $452.4M Revenue: $1.2B REVENUE $1.2B +0% Y/Y Gross profit: $799.1M · 66% margin GROSS PROFIT $799.1M 66% margin · +1% Y/Y Cost of revenue: $416.0M · 34% of revenue COST OF REVENUE $416.0M 34% of revenue Operating profit: $251.9M · 21% margin OPERATING PROFIT $251.9M 21% margin · +146% Y/Y Operating expenses: $547.2M · 45% of revenue OPERATING EXPENSES $547.2M 45% of revenue Net profit: $181.8M · 15% margin NET PROFIT $181.8M 15% margin · +148% Y/Y Tax & other: $70.0M · 6% of revenue TAX & OTHER $70.0M 6% of revenue R&D: $94.8M · 8% of revenue R&D $94.8M 8% of revenue SG&A: $452.4M · 37% of revenue SG&A $452.4M 37% of revenue
Gross profit $799.1M 66% margin · +1% Y/Y
Operating profit $251.9M 21% margin · +146% Y/Y
Net profit $181.8M 15% margin · +148% Y/Y
The full income statement, year by year

TECH among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: -0.4%, above 8% of 59 peers (their median 7.2%) REVENUE GROWTH -0.4% · above 8% Gross margin: 65.8%, above 54% of 50 peers (their median 64.2%) GROSS MARGIN 65.8% · above 54% Operating margin: 19.6%, above 70% of 50 peers (their median 13.4%) OPERATING MARGIN 19.6% · above 70% Net margin: 14.0%, above 64% of 59 peers (their median 9.5%) NET MARGIN 14.0% · above 64% FCF margin: 25.1%, above 91% of 55 peers (their median 15.2%) FCF MARGIN 25.1% · above 91% Return on capital: 7.4%, above 27% of 41 peers (their median 9.2%) RETURN ON CAPITAL 7.4% · above 27%
TECH Peer median Below the median

What changed

31 new risk paragraphs. 10-K filed Aug 24, 2026 against Aug 22, 2025.

Risk factors
31 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
3 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +4.7% vs revenue -0.4% (+5.1 pts)
  • Cash from operations $292.1M vs net income $181.9M (FY ending Jun 30, 2026)
  • Inventory +3.3% vs revenue -0.4% (+3.7 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Sufficiency of audit evidence over net sales
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

31 paragraphs in Risk Factors that were not in the 10-K filed Aug 22, 2025. Quoted as filed.

All 31 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Aug 22, 2025 10-K, ITEM 1A
    For instance, our use of animal-derived materials in certain products and manufacturing processes subjects us to regulatory, supply chain, quality, and reputational risks that could adversely affect our business. The sourcing, processing, importation, exportation, handling, storage, transportation and use of animal-derived materials are…
  2. Item 1A · new paragraph · not in the 10-K filed Aug 22, 2025 10-K, ITEM 1A
    The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operations. On June 25, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub. The Merger Agreement provides that, on the terms and subject to the…
  3. Item 1A · new paragraph · not in the 10-K filed Aug 22, 2025 10-K, ITEM 1A
    For many years, our Board has declared quarterly dividends. In the future, our Board may reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. While the Merger Agreement is in effect, we are prohibited from declaring, setting aside, making or paying any…
  4. Item 1A · new paragraph · not in the 10-K filed Aug 22, 2025 10-K, ITEM 1A
    Government authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law. Failure to obtain required regulatory clearances before marketing our products (or before implementing modifications to or promoting additional indications or uses of our products),…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025FY2026
Revenue$1.1B$1.2B$1.2B$1.2B
Net income$285.3M$168.1M$73.4M$181.8M
Operating cash flow$254.4M$299.0M$287.6M$292.1M
Free cash flow$216.1M$236.1M$256.6M$263.2M

Revenue, FY2017 to FY2026

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.2B ▼ 0.4% in FY2026

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Bio-Techne, Minneapolis, MN · from the 10-K filed Aug 24, 2026

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (“Bio-Techne”, “we”, “our”, “us” or the “Company”), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

Headquarters
Minneapolis, MN
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
June 30
Last results
Aug 12, 2026
Incorporated in
MN

Email alerts

Sources

The 10-K filed Aug 24, 2026 (open at SEC), compared with the 10-K filed Aug 22, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TECH/export.csv") into a cell.